These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 28421390)

  • 1. Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
    Hatake K; Ogura M; Takada K; Taniwaki M; Zhang F; Fujita T; Ando K
    Int J Hematol; 2017 Aug; 106(2):240-247. PubMed ID: 28421390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.
    Hillmen P; Robak T; Janssens A; Babu KG; Kloczko J; Grosicki S; Doubek M; Panagiotidis P; Kimby E; Schuh A; Pettitt AR; Boyd T; Montillo M; Gupta IV; Wright O; Dixon I; Carey JL; Chang CN; Lisby S; McKeown A; Offner F;
    Lancet; 2015 May; 385(9980):1873-83. PubMed ID: 25882396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
    Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
    Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
    Offner F; Robak T; Janssens A; Govind Babu K; Kloczko J; Grosicki S; Mayer J; Panagiotidis P; Schuh A; Pettitt A; Montillo M; Werner O; Vincent G; Khanna S; Hillmen P
    Br J Haematol; 2020 Sep; 190(5):736-740. PubMed ID: 32236950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Ogura M; Hatake K; Tobinai K; Uchida T; Suzuki T; Terui Y; Yokoyama M; Maruyama D; Mori M; Jewell RC; Katsura K; Hotta T
    Jpn J Clin Oncol; 2013 May; 43(5):466-75. PubMed ID: 23456745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
    Stilgenbauer S; Bosch F; Ilhan O; Kisro J; Mahé B; Mikuskova E; Osmanov D; Reda G; Robinson S; Tausch E; Turgut M; Wójtowicz M; Böttcher S; Perretti T; Trask P; Van Hoef M; Leblond V; Foà R
    Br J Haematol; 2021 Apr; 193(2):325-338. PubMed ID: 33605445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.
    Shah A
    Ann Pharmacother; 2014 Oct; 48(10):1356-61. PubMed ID: 25037849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
    Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
    Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
    Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
    Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia.
    Ogawa Y; Ogura M; Suzuki T; Ando K; Uchida T; Shirasugi Y; Tobinai K; Lee JH; Kase M; Katsura K; Hotta T
    Int J Hematol; 2013 Aug; 98(2):164-70. PubMed ID: 23846385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
    Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
    Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
    Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F
    Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
    Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I
    Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.
    Hillmen P; Gribben JG; Follows GA; Milligan D; Sayala HA; Moreton P; Oscier DG; Dearden CE; Kennedy DB; Pettitt AR; Nathwani A; Varghese A; Cohen D; Rawstron A; Oertel S; Pocock CF
    J Clin Oncol; 2014 Apr; 32(12):1236-41. PubMed ID: 24638012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ofatumumab in previously untreated chronic lymphocytic leukaemia. No clear advantages when added to chlorambucil.
    Prescrire Int; 2015 Nov; 24(165):262. PubMed ID: 26688893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
    Leblond V; Aktan M; Ferra Coll CM; Dartigeas C; Kisro J; Montillo M; Raposo J; Merot JL; Robson S; Gresko E; Bosch F; Stilgenbauer S; Foà R
    Haematologica; 2018 Nov; 103(11):1889-1898. PubMed ID: 29976743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.
    Panovská A; Němcová L; Nekvindová L; Špaček M; Šimkovič M; Papajík T; Brejcha M; Lysák D; Zuchnická J; Novák J; Starostka D; Poul H; Vrbacký F; Vodárek P; Urbanová R; Plevová K; Pospíšilová Š; Mašlejová S; Brychtová Y; Koriťáková E; Smolej L; Doubek M
    Hematol Oncol; 2020 Oct; 38(4):509-516. PubMed ID: 32400885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.